8-K Announcements
6Material company update
Mar 26, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Jan 23, 2026·SEC
Century Therapeutics, Inc.(IPSC)Earnings, Financials & Key Ratios
IPSC•NASDAQ
$2.31
$202M mkt cap·Price updated May 7, 2026
AboutCentury Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.Show more
- Revenue$109M+1556.8%
- EBITDA-$17M+86.2%
- Net Income-$10M+92.4%
- EPS (Diluted)-0.14+91.3%
- EBITDA Margin-15.82%+99.2%
- Operating Margin-15.82%+99.2%
- Net Margin-8.78%+99.5%
- ROE-5.98%+91.8%
- ROIC-8.81%+85.4%
- Debt/Equity0.25-24.1%
IPSC Key Insights
Century Therapeutics, Inc. (IPSC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 97 (top 3%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 10.1% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IPSC Price & Volume
Century Therapeutics, Inc. (IPSC) stock price & volume — 10-year historical chart
Loading chart...
IPSC Growth Metrics
Century Therapeutics, Inc. (IPSC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years175.88%
TTM1556.51%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM92.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM91.57%
Return on Capital
10 Years-33.92%
5 Years-32.15%
3 Years-31.18%
Last Year-8.09%
IPSC Recent Earnings
Century Therapeutics, Inc. (IPSC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (56%)
Q2 2026Latest
Mar 12, 2026EPS
$0.25
Est $0.28
+10.7%
Revenue
—
Est $62,500
Q4 2025
Nov 13, 2025EPS
$0.32
Est $0.39
+17.9%
Revenue
—
Est $83,330
Q3 2025
Aug 14, 2025EPS
$0.38
Est $0.38
+0.0%
Revenue
—
Est $25,000
Q2 2025
May 15, 2025EPS
$0.89
Est $0.31
+387.1%
Revenue
$109M
Est $41M
+164.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.25vs $0.28+10.7% | —vs $62,500 |
| Q4 2025 | Nov 13, 2025 | $0.32vs $0.39+17.9% | —vs $83,330 |
| Q3 2025 | Aug 14, 2025 | $0.38vs $0.38+0.0% | —vs $25,000 |
| Q2 2025 | May 15, 2025 | $0.89vs $0.31+387.1% | $109Mvs $41M+164.4% |
Based on last 12 quarters of dataView full earnings history →
IPSC Peer Comparison
Century Therapeutics, Inc. (IPSC) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 CELC | 5.66B | 130.71 | -46.19 | -179% | 0.85 | |||
 IOVA | 1.27B | 3.55 | -3.26 | 60.6% | -123.9% | -50.17% | 0.07 | |
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 296.54M | 3.03 | -1.68 | -100% | -5.23% | 0.66 |
Compare IPSC vs Peers
Century Therapeutics, Inc. (IPSC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IPSC Income Statement
Century Therapeutics, Inc. (IPSC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 5.2M | 2.23M | 6.59M | 109.16M |
| Revenue Growth % | - | - | - | - | -57.01% | 194.81% | 1556.76% |
| Cost of Goods Sold | 249K | 1.75M | 4.58M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -249K▲ 0% | -1.75M▼ 604.4% | -4.58M▼ 161.2% | 5.2M▲ 213.5% | 2.23M▼ 57.0% | 6.59M▲ 194.8% | 0▼ 100.0% |
| Gross Margin % | - | - | - | 100% | 100% | 100% | - |
| Gross Profit Growth % | - | -604.42% | -161.23% | 213.47% | -57.01% | 194.81% | -100% |
| Operating Expenses | 19.78M | 47.42M | 90.3M | 139.03M | 148.78M | 144.73M | 126.43M |
| OpEx % of Revenue | - | - | - | 2674.17% | 6656.87% | 2196.48% | 115.82% |
| Selling, General & Admin | 5.52M | 7.74M | 14.65M | 31.86M | 34.71M | 33.16M | 24M |
| SG&A % of Revenue | - | - | - | 612.75% | 1552.84% | 503.19% | 21.99% |
| Research & Development | 14.27M | 39.68M | 75.65M | 97.17M | 92.71M | 107.24M | 95.67M |
| R&D % of Revenue | - | - | - | 1869.07% | 4148.1% | 1627.62% | 87.64% |
| Other Operating Expenses | 0 | 0 | 0 | 10M | 21.36M | 4.33M | 6.76M |
| Operating Income | -20.03M▲ 0% | -49.18M▼ 145.5% | -94.88M▼ 92.9% | -133.83M▼ 41.0% | -146.55M▼ 9.5% | -138.14M▲ 5.7% | -17.27M▲ 87.5% |
| Operating Margin % | - | - | - | -2574.17% | -6556.87% | -2096.48% | -15.82% |
| Operating Income Growth % | - | -145.47% | -92.95% | -41.05% | -9.5% | 5.74% | 87.5% |
| EBITDA | -19.78M | -47.42M | -90.3M | -125.39M | -133.5M | -124.83M | -17.27M |
| EBITDA Margin % | - | - | - | -2411.83% | -5973.24% | -1894.57% | -15.82% |
| EBITDA Growth % | - | -139.7% | -90.42% | -38.86% | -6.47% | 6.49% | 86.17% |
| D&A (Non-Cash Add-back) | 249K | 1.75M | 4.58M | 8.44M | 13.04M | 13.3M | 0 |
| EBIT | -244.77M | -53.19M | -94.51M | -129.64M | -134.25M | -124.78M | 0 |
| Net Interest Income | 1.21M | 323K | -377K | 2.99M | 12.14M | 13.01M | 0 |
| Interest Income | 1.21M | 704K | 898K | 2.99M | 12.68M | 13.01M | 7.35M |
| Interest Expense | 0 | 381K | 1.27M | 0 | 540K | 0 | 0 |
| Other Income/Expense | -224.74M | -4.4M | -898K | 2.99M | 11.75M | 13.36M | 7.62M |
| Pretax Income | -244.77M▲ 0% | -53.58M▲ 78.1% | -95.78M▼ 78.8% | -130.84M▼ 36.6% | -134.79M▼ 3.0% | -124.78M▲ 7.4% | -9.65M▲ 92.3% |
| Pretax Margin % | - | - | - | -2516.66% | -6030.96% | -1893.7% | -8.84% |
| Income Tax | 0 | 0 | 43K | 91K | 1.88M | 1.79M | -68K |
| Effective Tax Rate % | 0% | 0% | -0.04% | -0.07% | -1.4% | -1.43% | 0.7% |
| Net Income | -244.77M▲ 0% | -53.58M▲ 78.1% | -95.82M▼ 78.9% | -130.93M▼ 36.6% | -136.67M▼ 4.4% | -126.57M▲ 7.4% | -9.58M▲ 92.4% |
| Net Margin % | - | - | - | -2518.41% | -6115.12% | -1920.87% | -8.78% |
| Net Income Growth % | - | 78.11% | -78.86% | -36.64% | -4.38% | 7.4% | 92.43% |
| Net Income (Continuing) | -244.77M | -53.58M | -95.82M | -130.93M | -136.67M | -126.57M | -9.58M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.49▲ 0% | -1.00▲ 77.7% | -1.74▼ 74.0% | -2.27▼ 30.5% | -2.30▼ 1.3% | -1.61▲ 30.0% | -0.14▲ 91.3% |
| EPS Growth % | - | 77.73% | -74% | -30.46% | -1.32% | 30% | 91.3% |
| EPS (Basic) | -4.49 | -1.00 | -1.74 | -2.27 | -2.30 | -1.61 | -0.14 |
| Diluted Shares Outstanding | 54.82M | 54.82M | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M |
| Basic Shares Outstanding | 54.82M | 54.82M | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
IPSC Balance Sheet
Century Therapeutics, Inc. (IPSC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 84.12M | 78.8M | 228.15M | 319.72M | 176.99M | 194.05M | 120.77M |
| Cash & Short-Term Investments | 81.54M | 75.75M | 222.88M | 315.5M | 172.74M | 189.29M | 117.11M |
| Cash Only | 44.06M | 27.21M | 56.45M | 84.27M | 47.32M | 58.44M | 61.85M |
| Short-Term Investments | 37.48M | 48.54M | 166.43M | 231.23M | 125.41M | 130.85M | 55.26M |
| Accounts Receivable | 123K | 908K | 250K | 780K | 665K | 1.52M | 0 |
| Days Sales Outstanding | - | - | - | 54.76 | 108.6 | 84.2 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 320K | 1.8M | 2.79M | 462K | 1.78M | 860K | 3.65M |
| Total Non-Current Assets | 6.77M | 27.98M | 209.22M | 166.82M | 183.7M | 159.16M | 102.94M |
| Property, Plant & Equipment | 2.49M | 24.78M | 69.82M | 111.73M | 92.08M | 90.85M | 66.17M |
| Fixed Asset Turnover | - | - | - | 0.05x | 0.02x | 0.07x | 1.65x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 9.39M | 0 | 0 | 0 | 34.2M | 34.2M |
| Long-Term Investments | 4.08M | 1.05M | 135.91M | 51.85M | 91.08M | 30.82M | 0 |
| Other Non-Current Assets | 206K | -7.24M | 3.49M | 3.24M | 541K | 3.3M | 2.57M |
| Total Assets | 90.9M▲ 0% | 106.78M▲ 17.5% | 437.38M▲ 309.6% | 486.54M▲ 11.2% | 360.69M▼ 25.9% | 353.22M▼ 2.1% | 223.7M▼ 36.7% |
| Asset Turnover | - | - | - | 0.01x | 0.01x | 0.02x | 0.49x |
| Asset Growth % | - | 17.47% | 309.62% | 11.24% | -25.87% | -2.07% | -36.67% |
| Total Current Liabilities | 2.99M | 12.11M | 15.65M | 29.82M | 17.85M | 129.78M | 20.23M |
| Accounts Payable | 1.55M | 8.08M | 7.6M | 5.45M | 2.74M | 3.08M | 4.77M |
| Days Payables Outstanding | 2.27K | 1.68K | 605.09 | - | - | - | - |
| Short-Term Debt | 0 | 0 | 1.04M | 6.5M | 1.51M | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 7.15M | 4.37M | 109.16M | 0 |
| Other Current Liabilities | 53K | 52K | 1.08M | 3.17M | 2.72M | 82K | 20.23M |
| Current Ratio | 28.10x | 6.51x | 14.57x | 10.72x | 9.92x | 1.50x | 5.97x |
| Quick Ratio | 28.10x | 6.51x | 14.57x | 10.72x | 9.92x | 1.50x | 5.97x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 179.76M | 201.08M | 25.48M | 153.99M | 158.09M | 62.07M | 44.54M |
| Long-Term Debt | 0 | 9.64M | 8.9M | 3.74M | 0 | 0 | 40.24M |
| Capital Lease Obligations | 0 | 11.68M | 14.56M | 38.7M | 46.66M | 48.96M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 4.37M | 4.3M |
| Other Non-Current Liabilities | 179.76M | 179.76M | 2.02M | 718K | 56K | 8.74M | 0 |
| Total Liabilities | 182.75M | 213.19M | 41.14M | 183.81M | 175.94M | 191.85M | 64.77M |
| Total Debt | 0 | 21.55M | 25.12M | 49.41M | 48.17M | 53.83M | 40.24M |
| Net Debt | -44.06M | -5.66M | -31.33M | -34.85M | 847K | -4.61M | -21.61M |
| Debt / Equity | - | - | 0.06x | 0.16x | 0.26x | 0.33x | 0.25x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | -129.07x | -74.42x | - | -271.38x | - | - |
| Total Equity | -91.86M▲ 0% | -106.41M▼ 15.8% | 396.24M▲ 472.4% | 302.74M▼ 23.6% | 184.75M▼ 39.0% | 161.36M▼ 12.7% | 158.94M▼ 1.5% |
| Equity Growth % | - | -15.84% | 472.36% | -23.6% | -38.97% | -12.66% | -1.5% |
| Book Value per Share | -1.68 | -1.94 | 7.20 | 5.24 | 3.11 | 2.05 | 1.84 |
| Total Shareholders' Equity | -91.86M | -106.41M | 396.24M | 302.74M | 184.75M | 161.36M | 158.94M |
| Common Stock | 1K | 1K | 5K | 6K | 6K | 9K | 9K |
| Retained Earnings | -238.77M | -292.34M | -388.17M | -519.1M | -655.77M | -782.34M | -791.92M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -3K | -3K | -650K | -2.46M | 108K | 324K | 30K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IPSC Cash Flow Statement
Century Therapeutics, Inc. (IPSC) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -16.17M | -41.27M | -89M | 14.05M | -88.35M | -110.14M | -103.88M |
| Operating CF Margin % | - | - | - | 270.28% | -3952.93% | -1671.5% | -95.16% |
| Operating CF Growth % | - | -155.25% | -115.66% | 115.79% | -728.72% | -24.66% | 5.68% |
| Net Income | -244.77M | -53.58M | -95.82M | -130.93M | -136.67M | -126.57M | -9.58M |
| Depreciation & Amortization | 249K | 1.4M | 3.75M | 8.44M | 13.04M | 13.3M | 13.1M |
| Stock-Based Compensation | 147K | 876K | 4.66M | 10.67M | 14.62M | 12.69M | 6.84M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 870K | -73K |
| Other Non-Cash Items | 225.95M | 5.17M | 1.21M | 1.93M | 11.28M | -1.15M | -114.16M |
| Working Capital Changes | 2.26M | 4.86M | -2.8M | 123.94M | 9.38M | -9.28M | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.23M | 2.06M | -1.85M | -4.79M | -2.36M | -1.47M | 1.56M |
| Cash from Investing | -19.83M | -22.76M | -298.34M | -13.13M | 61.13M | 47.48M | 107.5M |
| Capital Expenditures | -2.46M | -9.82M | -44.97M | -30.6M | -13.74M | -154K | 0 |
| CapEx % of Revenue | - | - | - | 588.65% | 614.59% | 2.34% | - |
| Acquisitions | 0 | 0 | 0 | -238.22M | 0 | -9.61M | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 24.17M | -4.72M | 0 | 238.22M | 0 | 0 | 158.68M |
| Cash from Financing | 74.84M | 47.69M | 417.77M | 27.16M | -9.72M | 74.56M | 173K |
| Debt Issued (Net) | 0 | 9.73M | 0 | 0 | -10.24M | 0 | 0 |
| Equity Issued (Net) | 1000K | 0 | 1000K | 1000K | 516K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 37.96M | 36.53M | 0 | 0 | 0 | 173K |
| Net Change in Cash | 38.84M▲ 0% | -16.34M▼ 142.1% | 30.43M▲ 286.3% | 28.08M▼ 7.7% | -36.94M▼ 231.5% | 11.91M▲ 132.2% | 3.8M▼ 68.1% |
| Free Cash Flow | -18.63M▲ 0% | -51.09M▼ 174.3% | -133.97M▼ 162.2% | -16.55M▲ 87.6% | -102.08M▼ 516.7% | -110.29M▼ 8.0% | -103.88M▲ 5.8% |
| FCF Margin % | - | - | - | -318.37% | -4567.52% | -1673.84% | -95.16% |
| FCF Growth % | - | -174.29% | -162.21% | 87.65% | -516.75% | -8.04% | 5.81% |
| FCF per Share | -0.34 | -0.93 | -2.44 | -0.29 | -1.72 | -1.40 | -1.20 |
| FCF Conversion (FCF/Net Income) | 0.07x | 0.77x | 0.93x | -0.11x | 0.65x | 0.87x | 10.84x |
| Interest Paid | 0 | 0 | 0 | 1.1M | 586K | 0 | 0 |
| Taxes Paid | 0 | 207K | 983K | 1.1M | 3.11M | 501K | 0 |
IPSC Key Ratios
Century Therapeutics, Inc. (IPSC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -66.13% | -37.46% | -56.07% | -73.14% | -5.98% |
| Return on Invested Capital (ROIC) | - | - | -56.29% | -31.72% | -48.47% | -60.52% | -8.81% |
| Gross Margin | - | - | - | 100% | 100% | 100% | - |
| Net Margin | - | - | - | -2518.41% | -6115.12% | -1920.87% | -8.78% |
| Debt / Equity | - | - | 0.06x | 0.16x | 0.26x | 0.33x | 0.25x |
| Interest Coverage | - | -129.07x | -74.42x | - | -271.38x | - | - |
| FCF Conversion | 0.07x | 0.77x | 0.93x | -0.11x | 0.65x | 0.87x | 10.84x |
| Revenue Growth | - | - | - | - | -57.01% | 194.81% | 1556.76% |
IPSC SEC Filings & Documents
Century Therapeutics, Inc. (IPSC) SEC filings — annual & quarterly reports (10-K, 10-Q)
IPSC Frequently Asked Questions
Century Therapeutics, Inc. (IPSC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Century Therapeutics, Inc. (IPSC) reported $109.2M in revenue for fiscal year 2025.
Century Therapeutics, Inc. (IPSC) grew revenue by 1556.8% over the past year. This is strong growth.
Century Therapeutics, Inc. (IPSC) reported a net loss of $9.6M for fiscal year 2025.
Dividend & Returns
Century Therapeutics, Inc. (IPSC) has a return on equity (ROE) of -6.0%. Negative ROE indicates the company is unprofitable.
Century Therapeutics, Inc. (IPSC) had negative free cash flow of $104.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More IPSC
Century Therapeutics, Inc. (IPSC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates